Hospital medicine (London, England : 1998) 2003-06-01

Leuprorelin: a leading role in advanced prostate cancer therapy.

Raj Persad

Index: Hosp. Med. 64(6) , 360-3, (2003)

Full Text: HTML

Abstract

Leuprorelin is a luteinizing hormone-releasing hormone analogue, licensed in the UK for the treatment of advanced prostate cancer. This review highlights the efficacy and tolerance of this agent and the benefits provided for developing patient-centred therapy and optimizing patient quality of life.

Related Compounds

  • Leuprolide TFA

Related Articles:

Estradiol, but not testosterone, heightens cortisol-mediated negative feedback on pulsatile ACTH secretion and ACTH approximate entropy in unstressed older men and women.

2014-05-01

[Am. J. Physiol. Regul. Integr. Comp. Physiol. 306(9) , R627-35, (2014)]

Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients.

2013-03-01

[Med. Oncol. 30(1) , 354, (2013)]

Novasure as a mechanical endometrial preparation agent in large uteri.

2012-01-01

[JSLS 16(4) , 537-41, (2012)]

Comprehensive management of diffuse leiomyomatosis in a patient with Alport syndrome.

2013-12-01

[P. R. Health Sci. J. 32(4) , 200-2, (2013)]

A rare case of lymphangiomyomatosis treated with leuprolide acetate: five-years follow-up.

2013-01-01

[Eur. J. Gynaecol. Oncol. 34(3) , 278-9, (2013)]

More Articles...